Every acronym in this glossary is sourced, dated, and cross-checked against a primary regulatory authority — not paraphrased from someone else’s glossary. It’s the same 165-term reference we use internally across CMC, GMP, and FDA/EMA regulatory engagements.
How this glossary is built
Each entry carries a preferred expansion, the regulatory domain it belongs to, a plain-language context note, an authority tier (Authoritative / ICH / GMP-Quality Standard / Industry Standard), and a direct link to its primary source — FDA, EMA, ICH, EDQM, CDISC, WHO-UMC, or an equivalent standards body. Where an acronym is genuinely ambiguous across domains (AI, CM, CPV, PMS, PV), we list every valid expansion rather than picking one and hiding the rest.
Start here — 15 foundational terms
The acronyms every regulatory, quality, and CMC conversation runs through.
FDA — Food and Drug Administration
US agency within HHS regulating drugs, biologics, devices, foods, etc. Source
EMA — European Medicines Agency
EU medicines regulatory agency. Source
ICH — International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
Global harmonization body for pharmaceutical guidelines. Source
CMC — Chemistry, Manufacturing, and Controls
Quality/technical product information in IND/NDA/ANDA/BLA submissions. Source
GMP — Good Manufacturing Practice
Manufacturing quality requirements/principles. Source
CGMP — Current Good Manufacturing Practice
US GMP requirements; often written cGMP/CGMP. Source
GCP — Good Clinical Practice
Clinical trial quality and ethics standard. Source
CAPA — Corrective and Preventive Action
Quality system process encompassing correction, root cause analysis, corrective action, preventive action, and effectiveness checks under ICH Q10. Source
ALCOA+ — Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available
FDA/MHRA data integrity principle set describing the attributes expected of GMP records; underlies RCR-003. Source
QbD — Quality by Design
Systematic approach to development emphasizing product/process understanding and control. Source
CQA — Critical Quality Attribute
Physical, chemical, biological, or microbiological property that should be within limits to ensure quality. Source
DI — Data Integrity
Completeness, consistency, accuracy, and trustworthiness of data. Source
QMS — Quality Management System
Formal system for managing quality. Source
CTD — Common Technical Document
ICH format for quality, nonclinical, and clinical information. Source
IND — Investigational New Drug Application
US application to begin clinical investigation of a drug/biologic. Source
The full glossary — 150 additional terms
General Regulatory & CMC Terminology (17 terms)
API — Active Pharmaceutical Ingredient
Drug substance or active ingredient in a drug product. Source
BR — Batch Record
Documented record of the manufacture of a specific batch, required under 21 CFR 211.188 / EU GMP Chapter 4 (see RCR-037, BATCH_RECORD). Source
CIOMS — Council for International Organizations of Medical Sciences
Source of cumulative ICH/PV glossary work. Source
CS — Control Strategy
Planned set of controls derived from product/process understanding. Source
DAR — Drug Application Review
FDA review context acronym in some FDA materials. Source
DUNS — Data Universal Numbering System
Business entity identifier historically used in regulatory systems. Source
FHIR — Fast Healthcare Interoperability Resources
HL7 standard for healthcare data exchange using modern web technologies. Source
GDP — Good Distribution Practice
Distribution quality system for medicinal products. Source
HL7 — Health Level Seven
Standards development organization and interoperability standards family. Source
IDMP — Identification of Medicinal Products
ISO standards for identifying and describing medicinal products. Source
ISO — International Organization for Standardization
International standards body. Source
LIMS — Laboratory Information Management System
System managing lab samples, tests, and results. Source
LOINC — Logical Observation Identifiers Names and Codes
Standard for lab/clinical observations. Source
NDC — National Drug Code
US identifier for listed drug products. Source
OPQ — Office of Pharmaceutical Quality
CDER office responsible for pharmaceutical quality assessment/inspection integration. Source
SME — Subject Matter Expert
Expert in a specific technical area. Source
WHO — World Health Organization
UN specialized agency for international public health. Source
EU / EMA Regulatory (17 terms)
AR — Assessment Report
EMA/regulatory assessment report context. Source
ASMF — Active Substance Master File
EU active substance master file mechanism. Source
CHMP — Committee for Medicinal Products for Human Use
EMA scientific committee for human medicines. Source
CMA — Conditional Marketing Authorisation
EU conditional approval pathway. Source
CVMP — Committee for Veterinary Medicinal Products
EMA committee for veterinary medicines. Source
DCP — Decentralised Procedure
EU procedure for authorization in multiple member states. Source
DDC — Drug-Device Combination
Combination of medicinal product and device elements. Source
GVP — Good Pharmacovigilance Practices
EU pharmacovigilance guidance modules. Source
MA — Marketing Authorisation
Authorization to market a medicinal product. Source
MAA — Marketing Authorisation Application
Application for marketing authorization. Source
MIDD — Model-Informed Drug Development
Use of modeling/simulation to inform drug development/regulatory decisions. Source
MRP — Mutual Recognition Procedure
EU procedure relying on mutual recognition between member states. Source
PIP — Paediatric Investigation Plan
EU pediatric development plan. Source
QP — Qualified Person
EU role responsible for batch certification/release. Source
RMP — Risk Management Plan
EU/international pharmacovigilance risk management plan. Source
SPC — Summary of Product Characteristics
EU product information document. Source
SPQS — Structured Product Quality Submission
EMA abbreviation related to structured product quality submission. Source
Pharmacovigilance & Drug Safety (13 terms)
ADR — Adverse Drug Reaction
A noxious/unintended response to a medicinal product where causal relationship is suspected. Source
AE — Adverse Event
Any untoward medical occurrence in a patient/administered subject. Source
AEFI — Adverse Event Following Immunisation
PV term for post-immunization adverse events. Source
MedDRA — Medical Dictionary for Regulatory Activities
Standardized medical terminology for regulatory communication. Source
PADER — Periodic Adverse Drug Experience Report
Periodic postmarketing safety report term. Source
PBRER — Periodic Benefit-Risk Evaluation Report
ICH periodic benefit-risk report format. Source
PMS — Post-Market Surveillance
Post-market monitoring of device/product safety/performance. Source
PSUR — Periodic Safety Update Report
Periodic safety report used in many regulatory settings. Source
PV — Pharmacovigilance
The science and activities relating to detection, assessment, understanding, and prevention of adverse effects of medicines (WHO-UMC glossary usage). Source
REMS — Risk Evaluation and Mitigation Strategy
FDA-required strategy to manage known/potential serious risks. Source
SAE — Serious Adverse Event
Adverse event meeting seriousness criteria. Source
UMC — Uppsala Monitoring Centre
WHO collaborating center for international drug monitoring. Source
WHO-UMC — World Health Organization-Uppsala Monitoring Centre
WHO collaborating center relationship in PV. Source
ICH Quality Guidelines (Q-Series) (12 terms)
ICH Q1 — Stability
ICH stability guideline family. Source
ICH Q10 — Pharmaceutical Quality System
Guideline on pharmaceutical quality system across lifecycle. Source
ICH Q11 — Development and Manufacture of Drug Substances
Guideline for drug substance development/manufacture. Source
ICH Q13 — Continuous Manufacturing of Drug Substances and Drug Products
Guideline for continuous manufacturing. Source
ICH Q14 — Analytical Procedure Development
Analytical procedure development guideline. Source
ICH Q2 — Analytical Validation
Validation of analytical procedures. Source
ICH Q3 — Impurities
Impurity guideline family. Source
ICH Q5 — Biotechnological/Biological Products
Quality guideline family for biotech/biological products. Source
ICH Q7 — Good Manufacturing Practice for Active Pharmaceutical Ingredients
GMP for APIs. Source
ICH Q9 — Quality Risk Management
Guideline for quality risk management. Source
PQS — Pharmaceutical Quality System
Management system directing and controlling pharmaceutical quality. Source
QRM — Quality Risk Management
Systematic process for assessment/control/communication/review of quality risk. Source
IDMP / Digital Product Identification (EMA SPOR) (9 terms)
API — Application Programming Interface
Software interface; used in EMA SPOR/IDMP digital context. Source
MPID — Medicinal Product Identifier
IDMP identifier for medicinal product. Source
OMS — Organisation Management System
EMA SPOR master data service for organization data. Source
PhPID — Pharmaceutical Product Identifier
IDMP identifier for pharmaceutical product concept. Source
PMS — Product Management Service
EMA SPOR service for product data. Source
RMS — Referentials Management Service
EMA SPOR service for referential master data. Source
SMS — Substance Management Service
EMA SPOR service for substance master data. Source
SPOR — Substance, Product, Organisation and Referential
EMA master data services program supporting ISO IDMP implementation. Source
SubID — Substance Identification
IDMP substance identification area. Source
Clinical Development & Trials (9 terms)
CRO — Contract Research Organization
External research service provider. Source
CTA — Clinical Trial Application
Application to conduct a clinical trial in many non-US jurisdictions. Source
EHR — Electronic Health Record
Electronic patient health record. Source
EudraCT — European Union Drug Regulating Authorities Clinical Trials
EU clinical trials database identifier/system context. Source
GLP — Good Laboratory Practice
Quality system for nonclinical lab studies. Source
IRB — Institutional Review Board
Ethics review committee in US clinical research. Source
RWD — Real World Data
Data relating to patient health status or healthcare delivery routinely collected. Source
RWE — Real World Evidence
Clinical evidence about usage/benefits/risks derived from RWD analysis. Source
SAP — Statistical Analysis Plan
Plan for statistical analysis of clinical study data. Source
FDA Regulatory Pathways & Applications (7 terms)
ANDA — Abbreviated New Drug Application
US generic drug application pathway. Source
BLA — Biologics License Application
US application for licensure of a biological product. Source
DMF — Drug Master File
Confidential submission to FDA to support applications. Source
IR — Information Request
FDA request during application review. Source
NDA — New Drug Application
US drug marketing application. Source
NME — New Molecular Entity
Drug containing no active moiety previously approved by FDA. Source
RLD — Reference Listed Drug
Listed drug relied upon by ANDA applicant. Source
FDA Inspection & Enforcement Classification (7 terms)
BIMO — Bioresearch Monitoring
FDA program for clinical/nonclinical research compliance oversight. Source
EIR — Establishment Inspection Report
FDA report documenting the conduct and findings of an establishment inspection. Source
FDA 483 — FDA Form 483 (Inspectional Observations)
List of inspectional observations issued at the conclusion of an FDA inspection under FD&C Act Section 704(b); underlies RCR-008. Source
NAI — No Action Indicated
FDA inspection classification indicating no objectionable conditions or practices were found during the inspection. Source
OAI — Official Action Indicated
FDA inspection classification indicating objectionable conditions or practices were found and regulatory and/or administrative action is recommended or indicated. Source
PAI — Pre-Approval Inspection
Inspection supporting pending application approval. Source
VAI — Voluntary Action Indicated
FDA inspection classification indicating objectionable conditions or practices were found but the agency is not prepared to take or recommend regulatory or administrative action. Source
Process Validation & Equipment Qualification (7 terms)
CPV — Continued Process Verification
FDA Stage 3 process validation lifecycle activity: ongoing assurance during commercial production that the process remains in a state of control (see RCR-013). Source
CPV — Continuous Process Verification
ICH Q8(R2) / EU GMP Annex 15 framing: an alternative approach to process validation using continuous, real-time quality assurance during production. Source
IQ — Installation Qualification
First stage of equipment/utility qualification: documented verification that equipment/systems are installed correctly per specifications. Source
OQ — Operational Qualification
Second stage of equipment/utility qualification: documented verification that equipment/systems operate as intended across expected operating ranges. Source
PQ — Performance Qualification
Third stage of equipment/utility qualification (after IQ and OQ) demonstrating that equipment consistently performs as intended under actual operating conditions (Annex 15, PIC/S PI 006). Source
PQ — Process Qualification
FDA Stage 2 process validation activity: confirming the process design is capable of reproducible commercial manufacturing (FDA Process Validation Guidance, 2011). Source
PV — Process Validation
Lifecycle-based approach (process design, process qualification, continued process verification) demonstrating a manufacturing process reliably delivers quality product (see RCR-014, PROCESS_VALIDATION). Source
GMP Quality Systems & Lab Controls (6 terms)
APR — Annual Product Review
US FDA-terminology periodic review of product/process data and trends required under 21 CFR 211.180(e); the EU equivalent is the Product Quality Review (PQR). Source
OOS — Out-of-Specification
Test result that falls outside established acceptance criteria/specifications, requiring a documented investigation (see RCR-005). Source
OOT — Out-of-Trend
A result or pattern that deviates from the expected trend even if within specification, which may warrant investigation (see RCR-006). Source
PQR — Product Quality Review
EU GMP Chapter 1 terminology for the periodic review of product/process data and trends; the US equivalent is the Annual Product Review (APR). Source
RCA — Root Cause Analysis
Systematic investigation practice to identify the underlying system-level cause of a deviation, complaint, or CAPA trigger (see RCR-035, ROOT_CAUSE). Source
SOP — Standard Operating Procedure
Controlled written procedure. Source
Compendial & Pharmacopoeial Standards (6 terms)
CEP — Certificate of Suitability to the Monographs of the European Pharmacopoeia
EDQM certificate supporting Ph. Eur. monograph suitability for substances. Source
EDQM — European Directorate for the Quality of Medicines & HealthCare
Council of Europe directorate for Ph. Eur., standard terms, CEPs. Source
OMCL — Official Medicines Control Laboratory
Network/labs for medicines control testing. Source
Ph. Eur. — European Pharmacopoeia
European pharmacopoeial standard. Source
USP — United States Pharmacopeia
Official compendium/standards body context. Source
USP-NF — United States Pharmacopeia-National Formulary
Official compendial standard combination. Source
Post-Approval Change & Lifecycle Management (5 terms)
CBE — Changes Being Effected
Supplement category allowing certain changes before approval after submission. Source
ICH Q12 — Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
Guideline for post-approval lifecycle management. Source
PACMP — Post-Approval Change Management Protocol
Protocol describing how future post-approval changes will be managed/reported. Source
PAM — Postapproval Manufacturing Change
Manufacturing change after approval. Source
PAS — Prior Approval Supplement
Supplement requiring FDA approval before implementation. Source
GMP & Manufacturing (5 terms)
CCS — Contamination Control Strategy
A holistic, documented strategy across a sterile manufacturing facility to control contamination risk, required under the revised EU GMP Annex 1 (2022) (see RCR-032). Source
CDMO — Contract Development and Manufacturing Organization
External development and manufacturing service provider. Source
CM — Continuous Manufacturing
A mode of pharmaceutical manufacturing in which material is continuously fed into and product continuously removed from a process, as addressed in ICH Q13. Source
CM — Contract Manufacturing
Manufacturing performed by an external contract manufacturer/contract manufacturing organization (CMO) on behalf of a sponsor or marketing authorization holder. Source
CMO — Contract Manufacturing Organization
External manufacturer. Source
CMC / Quality by Design (5 terms)
CPP — Critical Process Parameter
Process parameter whose variability can affect a CQA. Source
DoE — Design of Experiments
A statistical methodology used within Quality by Design to understand the relationship between process variables and outputs (see RCR-010, QBD_DOE). Source
ICH Q8 — Pharmaceutical Development
Guideline on pharmaceutical development. Source
PAR — Proven Acceptable Range
Range of a process parameter shown to produce acceptable quality. Source
QTPP — Quality Target Product Profile
A prospective summary of the quality characteristics a drug product should possess, forming the basis for identifying CQAs under ICH Q8(R2) (see RCR-011). Source
Clinical Data Standards (CDISC) (4 terms)
AAI — Acronyms, Abbreviations, and Initials
CDISC glossary category for short forms. Source
ADaM — Analysis Data Model
FDA/PMDA clinical data submission analysis dataset standard. Source
CDISC — Clinical Data Interchange Standards Consortium
Clinical research data standards organization. Source
SDTM — Study Data Tabulation Model
Clinical study tabulation dataset standard. Source
Digital Regulatory & CMC Modernization (3 terms)
AI — Artificial Intelligence
Computational systems used to support authoring, knowledge management, risk detection, or review preparation in CMC contexts (see RCR-028, AI_IN_CMC). Source
KASA — Knowledge-aided Assessment and Structured Application
FDA OPQ structured quality assessment/knowledge management initiative. Source
PQ/CMC — Pharmaceutical Quality / Chemistry, Manufacturing, and Controls
FDA pharmaceutical quality CMC structured data/submission modernization context. Source
Toxicology & Impurity Assessment (3 terms)
AI — Acceptable Intake
A toxicological threshold representing the estimated daily intake of a substance considered to pose negligible risk (used in impurity/genotoxicity assessments, e.g., ICH M7 context). Source
PDE — Permitted Daily Exposure
Health-based exposure limit concept. Source
QSAR — Quantitative Structure-Activity Relationship
Computational prediction relationship for chemical structure/activity. Source
FDA Organization & Centers (3 terms)
CBER — Center for Biologics Evaluation and Research
FDA center for many biological products, vaccines, blood, gene/cell therapy. Source
CDER — Center for Drug Evaluation and Research
FDA center for drugs and many therapeutic biologics. Source
CDRH — Center for Devices and Radiological Health
FDA center for devices and radiological health. Source
Regulatory Regions & Government Bodies (3 terms)
CFR — Code of Federal Regulations
Codified US federal regulations, including 21 CFR. Source
EU — European Union
European Union. Source
HHS — Department of Health and Human Services
FDA parent department. Source
Medical Terminology & Coding (3 terms)
LLT — Lowest Level Term
MedDRA hierarchy level. Source
MSSO — Maintenance and Support Services Organization
Organization maintaining and distributing MedDRA. Source
PT — Preferred Term
MedDRA hierarchy level. Source
Data Integrity (1 terms)
ER/ES — Electronic Records / Electronic Signatures
Electronic records and electronic signatures compliance area. Source
FDA Establishment & Facility Identification (1 terms)
FEI — Facility Establishment Identifier
FDA identifier associated with a facility or establishment; distinct from establishment registration status and not a substitute for confirming current registration/listing obligations. Source
Drug Master Files & Cross-Referencing (1 terms)
LOA — Letter of Authorization
Authorization that permits FDA to reference a DMF or other submitted information in support of an application; must be current/valid for review use. Source
International Regulatory Authorities (1 terms)
NMPA — National Medical Products Administration
Chinese regulatory authority. Source
Medical Devices (1 terms)
UDI — Unique Device Identifier
Device identification system. Source
Regulatory Submission Formats (CTD/eCTD) (1 terms)
eCTD — Electronic Common Technical Document
Electronic submission format implementing CTD structure. Source
Need this applied to your submission, not just defined?
XGene Consulting helps CMC and regulatory teams turn terminology into defensible, submission-ready strategy — from Module 3 authorship to FDA 483 and Warning Letter remediation.